21. P286 Bariatric surgery in inflammatory bowel disease: outcome and safety from a GETAID registry population. (25th January 2019) Authors: Reenaers, C; Nachury, M; Stefanescu, C; Pineton de Chambrun, G; Laharie, D; Boileve, J; Viennot, S; Peyrin-Biroulet, L; Roblin, X; Grimaud, J-C; Bouguen, G; Nahon, S; Goutorbe, F; Coffin, B Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. P319 Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study. (30th January 2023) Authors: Kobayashi, T; Dignass, A; Roblin, X; Fujitani, Y; Oortwijn, A; Jamoul, C; Hibi, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis. (21st January 2022) Authors: Veyrard, P; Pellet, G; Laharie, D; Nachury, M; Juillerat, P; Altwegg, R; Nancey, S; Fumery, M; Allez, M; Tran minh, M L; Roblin, X Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. P398 The early appearance of anti-drug antibodies during the induction phase predicts the clinical response of adalimumab and infliximab in IBD. (15th January 2020) Authors: Roblin, X; williet, N; veyrard, P; boschetti, G; berger, A E; nancey, S; flourie, B; paul, S Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. P413 A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn's disease. (25th January 2019) Authors: Dulai, P S; Amiot, A; Peyrin-Biroulet, L; Singh, S; Serrero, M; Jairath, V; Filippi, J; Pariente, B; Loftus Jr, E V; Roblin, X; Kane, S; Buisson, A; Siegel, C A; Bouhnik, Y; Sandborn, W J; Lasch, K; Rosario, M; Feagan, B G; Bojic, D; Trang-Poisson, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. P426 In failure of non-optimised adalimumab (ADA) with therapeutic serum levels, a change in biotherapy class is greater than an intensification of ADA dose in IBD patients. (15th January 2020) Authors: Roblin, X; genin, C; williet, N; veyrard, P; boschetti, G; berger, A E; flourie, B; nancey, S; Paul, S Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. P439 Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease. (21st January 2022) Authors: Roblin, X; Bastide, L; Veyrard, P; Berger, A E; Paul, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?. (21st January 2022) Authors: Fumery, M; Nancey, S; Filippi, J; Altwegg, R; Hebuterne, X; Boschetti, G; Veyrard, P; Yzet, C; Paul, S; Roblin, X Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. P494 Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study. (30th January 2023) Authors: Abdelmoula, A; Chateau, T; Hupe, M; Boschetti, G; Roblin, X; Nancey, S; Mathieu, N Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i625 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study. (27th May 2021) Authors: Fumery, M; Filippi, J; Abitbol, V; Biron, A; Laharie, D; Serrero, M; Altwegg, R; Bouhnik, Y; Peyrinbiroulet, L; Gilletta, C; Roblin, X; Pineton de Chambrun, G; Vuitton, L; Bourrier, A; Nancey, S; Gornet, J M; Nahon, S; Bouguen, G; Viennot, S; Pariente, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗